InBody Co (XKRX:041830) ROCE %: 24.75% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKRX:041830 InBody Co Ltd XKRX:041830
88 GF Score
Price ₩58,900.00
GF Value ₩35,473.99
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is InBody Co ROCE %?

InBody Co XKRX:041830 -3.60% 88 ROCE % is 24.75% as of Jun. 2026. GuruFocus rates XKRX:041830 with a GF Score™ of 88/100 and a GF Value™ of ₩35,473.99 (Significantly Overvalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. InBody Co's annualized ROCE % for the quarter that ended in Jun. 2026 was 24.75%.

InBody Co  (XKRX:041830) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

InBody Co ROCE % Related Terms

InBody Co ROCE % Historical Data

* Premium members only.

The historical data trend for InBody Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InBody Co ROCE % Chart

InBody Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.03 20.74 18.70 16.47 12.86

InBody Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.04 16.83 12.98 21.66 24.75
XKRX:041830
88GF Score
InBody Co Ltd XKRX:041830
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InBody Co ROCE % Calculation

InBody Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=39112.289/( ( (305816.656 - 25822.903) + (361061.686 - 32880.384) )/ 2 )
=39112.289/( (279993.753+328181.302)/ 2 )
=39112.289/304087.5275
=12.86 %

InBody Co's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=85494.344/( ( (381133.62 - 43462.233) + (388431.429 - 35204.766) )/ 2 )
=85494.344/( ( 337671.387 + 353226.663 )/ 2 )
=85494.344/345449.025
=24.75 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 24.75% mean?
InBody Co (XKRX:041830) has a ROCE % of 24.75% as of Jun. 2026.
Is InBody Co's ROCE % too high?
InBody Co's current ROCE % is 24.75%. The Medical Devices & Instruments industry median ROCE % is 2.99. InBody Co's value of 24.75% is 727.8% above this industry median. Overall, InBody Co has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InBody Co's ROCE % compare to ABT and SYK?
InBody Co's ROCE % of 24.75% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.99. InBody Co's value of 24.75% is 727.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.99, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InBody Co's current ROCE % of 24.75% is 727.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InBody Co's current ROCE % is 24.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InBody Co stock overvalued right now?
Based on GuruFocus' analysis, InBody Co (XKRX:041830) is currently considered Significantly Overvalued. The stock's GF Value™ is ₩35,473.99, compared to a current price of ₩58,900.00 — trading 66% above its estimated fair value. The current ROCE % is 24.75% and 727.8% above the Medical Devices & Instruments industry median of 2.99. InBody Co's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For InBody Co (XKRX:041830), the current ROCE % is 24.75% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InBody Co (XKRX:041830) Overvalued in 2026?

Based on GuruFocus' analysis, InBody Co stock appears to be overvalued. The current stock price of ₩58,900.00 is trading 66% above its estimated GF Value™ of ₩35,473.99. GuruFocus considers InBody Co to be Significantly Overvalued.

Key valuation signals for XKRX:041830:

  • ROCE %: 24.75%
  • GF Value™: ₩35,473.99 vs. price of ₩58,900.00 (66% above fair value)
  • GF Score™: 88/100 with 1 warning sign
  • Industry Position: 727.8% above the Medical Devices & Instruments median

No single metric tells the full story. See the XKRX:041830 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InBody Co Business Description

Address 54, Nonhyeon-ro 2-gil, Gangnam-gu, Seoul, KOR, 135-960
InBody Co Ltd is a Korea-based company engaged in the manufacturing and distribution of body composition analyzers. The company mainly produces body composition analyzers under the brand name InBody and Lookin'Body. It's InBody series products include InBody720, InBody570, InBody230, InBody J30, and InBody S10.
88GF Score

Get the complete analysis for XKRX:041830

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₩58,900.00
Price
₩35,473.99
GF Value